

## INDEPENDENT AUDITOR'S REPORT

To the Members of Caraco Pharmaceuticals Private Limited

### Report on the Audit of the Ind AS Financial Statements

#### Opinion

We have audited the accompanying Ind AS financial statements of Caraco Pharmaceuticals Private Limited ("the Company"), which comprise the Balance sheet as at March 31, 2026, the Statement of profit and loss, including the statement of other comprehensive income, the Cash Flow Statement and the Statement of Changes in Equity for the year then ended, and notes to the Ind AS financial statements, including a summary of material accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Ind AS financial statements give the information required by the Companies Act, 2013, as amended ("the Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2026, its loss including other comprehensive income, its cash flows and the changes in equity for the year ended on that date.

#### Basis for Opinion

We conducted our audit of the Ind AS financial statements in accordance with the Standards on Auditing (SAs), as specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the 'Auditor's Responsibilities for the Audit of the Ind AS Financial Statements' section of our report. We are independent of the Company in accordance with the 'Code of Ethics' issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the Ind AS financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Ind AS financial statements.

#### Other Information

The Company's Board of Directors is responsible for the other information. The other information comprises Board report but does not include Ind AS financial statements and our auditor's report thereon.

Our opinion on the Ind AS financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the Ind AS financial statements, our responsibility is to read the other information and, in doing so, consider whether such other information is materially inconsistent with the Ind AS financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

## Responsibility of Management for the Ind AS Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these Ind AS financial statements that give a true and fair view of the financial position, financial performance including other comprehensive income, cash flows and changes in equity of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) specified under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Ind AS financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Ind AS financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

## Auditor's Responsibilities for the Audit of the Ind AS Financial Statements

Our objectives are to obtain reasonable assurance about whether the Ind AS financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Ind AS financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Ind AS financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to Ind AS financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Ind AS financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Ind AS financial statements, including the disclosures, and whether the Ind AS financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

#### Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the "Annexure 1" a statement on the matters specified in paragraphs 3 and 4 of the Order.
2. As required by Section 143(3) of the Act, we report, to the extent applicable, that:
  - (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit;
  - (b) In our opinion, proper books of account as required by law have been kept by the Company, so far as it appears from our examination of those books except for the matter stated in the paragraph (i)(vi) below on reporting under Rule 11(g);
  - (c) The Balance Sheet, the Statement of Profit and Loss including the Statement of Other Comprehensive Income, the Cash Flow Statement and Statement of Changes in Equity dealt with by this Report are in agreement with the books of account;
  - (d) In our opinion, the aforesaid Ind AS financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Companies (Indian Accounting Standards) Rules, 2015 as amended;
  - (e) On the basis of the written representations received from the directors as on March 31, 2026 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2026 from being appointed as a director in terms of Section 164 (2) of the Act;
  - (f) The modification relating to the maintenance of accounts and other matters connected therewith are as stated in paragraph (b) above on reporting under Section 143(3)(b) and paragraph i(vi) below on reporting under Rule 11(g).

- (g) With respect to the adequacy of the internal financial controls with reference to these Ind AS financial statements and the operating effectiveness of such controls, refer to our separate Report in "Annexure 2" to this report;
- (h) The provisions of section 197 read with Schedule V of the Act are not applicable to the Company for the year ended March 31, 2026;
- (i) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended in our opinion and to the best of our information and according to the explanations given to us:
  - i. The Company does not have any pending litigations which would impact its financial position.
  - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
  - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
  - iv.
    - a) The management has represented that, to the best of its knowledge and belief, and read with note 22(e) to the Ind AS financial statements, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; s
    - b) The management has represented that, to the best of its knowledge and belief, and read with note 22(f) to the Ind AS financial statements, no funds have been received by the Company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and
    - c) Based on such audit procedures performed that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (a) and (b) contain any material misstatement.
  - v. No Dividend has been declared or paid during the year by the Company .
  - vi. Based on our examination which included test checks, the Company has used accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant

transactions recorded in the software. Further, during the course of our audit we did not come across any instance of audit trail feature being tampered with. Additionally, the audit trail of relevant prior years has been preserved by the Company in accordance with statutory record-retention requirements to the extent it was enabled and recorded in those respective years, except that for one applications where the audit trail relating to direct changes made using privileged/administrative access rights has not been preserved for the period May 24 to November 24, as stated in the note 23 to the standalone Ind AS financial statements.

For S R B C & CO LLP  
Chartered Accountants  
ICAI Firm Registration Number: 324982E/E300003

per Parag Gandhi  
Partner  
Membership Number: 136252  
UDIN: 26136252VEAXFB6243  
Place of Signature: Pune  
Date: May 20, 2026

Annexure '1' referred to in paragraph under the heading "Report on other legal and regulatory requirements" of our report of even date

Re: Caraco Pharmaceuticals Private Limited (the "Company")

In terms of the information and explanations sought by us and given by the Company and the books of account and records examined by us in the normal course of audit and to the best of our knowledge and belief, we state that:

- (i) (a)(A) According to the information and explanations given by management, the Company does not hold any property, plant and equipment. Accordingly, the requirement to report on clause 3(i)(a)(A) of the Order is not applicable to the Company.
- (a)(B) The Company has not capitalized any intangible assets in the books of the Company and accordingly, the requirement to report on clause 3(i)(a)(B) of the Order is not applicable to the Company.
- (b) The Company does not hold any property, plant and equipment and accordingly, the requirement to report on clause 3(i)(b) of the Order is not applicable to the Company.
- (c) There is no immovable property held by the Company and accordingly, the requirement to report on clause 3(i)(c) of the Order is not applicable to the Company.
- (d) The Company does not hold any property, plant and equipment or intangible assets and accordingly, the requirement to report on clause 3(i)(d) of the Order is not applicable to the Company.
- (e) There are no proceedings initiated or pending against the Company for holding any benami property under the Prohibition of Benami Property Transactions Act, 1988 and rules made thereunder.
- (ii) (a) The Company does not hold any inventory. Accordingly, the requirement to report on clause 3(ii)(a) of the Order is not applicable to the Company.
- (b) The Company has not been sanctioned working capital limits in excess of INR five crore in aggregate from banks or financial institutions during the year on the basis of security of current assets. Accordingly, the requirement to report on clause 3(ii)(b) of the Order is not applicable to the Company.
- (iii) During the year the Company has not made any investments in, provided any guarantee or security or granted any loans or advances in the nature of loans, secured or unsecured, to companies, firms, Limited Liability Partnerships or any other parties. Accordingly, the requirement to report on clause 3(iii)(a) to (f) of the Order is not applicable to the Company.
- (iv) There are no loans, investments, guarantees, and security in respect of which provisions of Section 185 and 186 of the Companies Act, 2013 are applicable and accordingly, the requirement to report on clause 3(iv) of the Order is not applicable to the Company.

- (v) The Company has neither accepted any deposits from the public nor accepted any amounts which are deemed to be deposits within the meaning of sections 73 to 76 of the Companies Act and the rules made thereunder, to the extent applicable. Accordingly, the requirement to report on clause 3(v) of the Order is not applicable to the Company.
- (vi) The Company is not in the business of sale of any goods or provision of such services as prescribed. Accordingly, the requirement to report on clause 3(vi) of the Order is not applicable to the Company.
- (vii) (a) The Company is regular in depositing with appropriate authorities undisputed statutory dues including goods and services tax, provident fund, employees' state insurance, income-tax, duty of customs, cess and other statutory dues applicable to it. According to the information and explanations given to us and based on audit procedures performed by us, no undisputed amounts payable in respect of these statutory dues were outstanding, at the year end, for a period of more than six months from the date they became payable.  
  
(b) There are no dues of goods and services tax, provident fund, employees' state insurance, income tax, sales-tax, service tax, customs duty, excise duty, value added tax, cess, and other statutory dues which have not been deposited on account of any dispute.
- (viii) The Company has not surrendered or disclosed any transaction, previously not recorded in the books of account, in the tax assessments under the Income Tax Act, 1961 as income during the year. Accordingly, the requirement to report on clause 3(viii) of the Order is not applicable to the Company.
- (ix) (a) The Company has not defaulted in repayment of loans or other borrowings or in the payment of interest thereon to any lender.  
(b) The Company has not been declared a willful defaulter by any bank or financial institution or government or any government authority.  
  
(c) Term loans were applied for the purpose for which the loans were obtained.  
  
(d) On an overall examination of the Ind AS financial statements of the Company, no funds raised on short-term basis have been used for long-term purposes by the Company.  
  
(e) The Company does not have any subsidiary, associate or joint venture. Accordingly, the requirement to report on Clause 3(ix)(e) of the Order is not applicable to the Company.  
  
(f) The Company does not have any subsidiary, associate or joint venture. Accordingly, the requirement to report on Clause 3(ix)(f) of the Order is not applicable to the Company.
- (x) (a) The Company has not raised any money during the year by way of initial public offer/ further public offer (including debt instruments) hence, the requirement to report on clause 3(x)(a) of the Order is not applicable to the Company.  
  
(b) The Company has not made any preferential allotment or private placement of shares /fully or partially or optionally convertible debentures during the year under audit and hence, the requirement to report on clause 3(x)(b) of the Order is not applicable to the Company and hence not reported upon.

- (xi) (a) No fraud by the Company or no fraud on the Company has been noticed or reported during the year.
- (b) During the year, no report under sub-section 12 of section 143 of the Companies Act, 2013 has been filed by secretarial auditor or by us in Form ADT-4, as prescribed under Rule 13 of Companies (Audit and Auditors) Rules, 2014, with the Central Government.
- (c) As represented to us by management, there are no whistle blower complaints received by the Company during the year.
- (xii) The Company is not a Nidhi Company as per the provisions of the Companies Act, 2013. Therefore, the requirement to report on clause 3(xii)(a) to (c) of the Order is not applicable to the Company.
- (xiii) Transactions with the related parties are in compliance with section 188 of Companies Act, 2013 where applicable and the details have been disclosed in the notes to the Ind AS financial statements, as required by the applicable accounting standards. The provisions of section 177 are not applicable to the Company and accordingly reporting under clause 3(xiii) insofar as it relates to section 177 of the Act is not applicable to the Company.
- (xiv) The Company does not have an internal audit system and is not required to have an internal audit system under the provisions of Section 138 of the Companies Act, 2013. Therefore, the requirement to report under clause 3(xiv)(a) of the Order is not applicable to the Company
- (xv) The Company has not entered into any non-cash transactions with its directors or persons connected with its directors and hence the requirement to report on clause 3(xv) of the Order is not applicable to the Company.
- (xvi) (a) The provisions of section 45-IA of the Reserve Bank of India Act, 1934 (2 of 1934) are not applicable to the Company. Accordingly, the requirement to report on clause (xvi)(a) of the Order is not applicable to the Company.
- (b) The Company is not engaged in any Non-Banking Financial or Housing Finance activities. Accordingly, the requirement to report on clause (xvi)(b) of the Order is not applicable to the Company.
- (c) The Company is not a Core Investment Company as defined in the regulations made by Reserve Bank of India. Accordingly, the requirement to report on clause 3(xvi)(c) of the Order is not applicable to the Company.
- (d) Based on information and explanation provided by the management of the Company, the group does not have more than one Core Investment Company as a part of the Group, hence, the requirement to report on clause 3(xvi)(d) of the Order is not applicable to the Company. We have not, however, separately evaluated whether the information provided by the management is accurate and complete.

- (xvii) The Company has incurred cash losses amounting to INR 73.8 thousands in the current year and INR 64.7 thousands in the immediately preceding financial year respectively.
- (xviii) There has been no resignation of the statutory auditors during the year. Accordingly, the requirement to report on clause 3(xviii) of the Order is not applicable to the Company.
- (xix) On the basis of the financial ratios disclosed in note 19 to the Ind AS financial statements, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the Ind AS financial statements, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions and considering the company's current liabilities exceeds the current assets by Rs. 484.9 thousand, the Company has obtained the letter of financial support from the Holding Company, nothing has come to our attention, which causes us to believe that Company is not capable of meeting its liabilities, existing at the date of balance sheet, as and when they fall due within a period of one year from the balance sheet date.
- We, further state that this is not an assurance as to the future viability of the Company and our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.
- (xx) The provisions of Section 135 to the Companies Act, 2013 in relation to Corporate Social Responsibility is not applicable to the Company. Accordingly, the requirement to report on clause 3(xx)(a) and 3(xx)(b) of the Order is not applicable to the Company.

For S R B C & CO LLP  
Chartered Accountants  
ICAI Firm Registration Number: 324982E/E300003

per Parag Gandhi  
Partner  
Membership Number: 136252  
UDIN: 26136252VEAXFB6243  
Place of Signature: Pune  
Date: May 20, 2026

Annexure 2 to the Independent Auditor's Report of even date on the financial statements of Caraco Pharmaceuticals Private Limited

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (the "Act")

We have audited the internal financial controls with reference to Ind AS financial statements of Caraco Pharmaceuticals Private Limited (the "Company") as of March 31, 2026 in conjunction with our audit of the Ind AS financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's Management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India ("ICAI"). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the companies Act 2013.

Auditor's Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls with reference to these Ind AS financial statements based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, as specified under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls, both issued by ICAI. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to these Ind AS financial statements was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to these Ind AS financial statements and their operating effectiveness. Our audit of internal financial controls with reference to Ind AS financial statements included obtaining an understanding of internal financial controls with reference to these Ind AS financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the Ind AS financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls with reference to these Ind AS financial statements.

#### Meaning of Internal Financial Controls With Reference to these Ind AS financial statements

A company's internal financial controls with reference to Ind AS financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of Ind AS financial statements for external purposes in accordance with generally accepted accounting principles.

A company's internal financial controls with reference to Ind AS financial statements includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of Ind AS financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the Ind AS financial statements.

#### Inherent Limitations of Internal Financial Controls With Reference to financial statements

Because of the inherent limitations of internal financial controls with reference to Ind AS financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to Ind AS financial statements to future periods are subject to the risk that the internal financial control with reference to Ind AS financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

#### Opinion

In our opinion, the Company has, in all material respects, adequate internal financial controls with reference to Ind AS financial statements and such internal financial controls with reference to Ind AS financial statements were operating effectively as at March 31, 2026, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note issued by the ICAI.

For S R B C & CO LLP  
Chartered Accountants  
ICAI Firm Registration Number: 324982E/E300003

per Parag Gandhi  
Partner  
Membership Number: 136252  
UDIN: 26136252VEAXFB6243  
Place of Signature: Pune  
Date: May 20, 2026

**CARACO PHARMACEUTICALS PRIVATE LIMITED**  
**BALANCE SHEET as at MARCH 31, 2026**

₹ in Thousand

| Particulars                                                                            | Notes | As at<br>March 31, 2026 | As at<br>March 31, 2025 |
|----------------------------------------------------------------------------------------|-------|-------------------------|-------------------------|
| <b>ASSETS</b>                                                                          |       |                         |                         |
| <b>Current assets</b>                                                                  |       |                         |                         |
| Financial assets                                                                       |       |                         |                         |
| (i) Cash and cash equivalents                                                          | 3     | 11.7                    | 2.8                     |
| <b>Total current assets</b>                                                            |       | <b>11.7</b>             | <b>2.8</b>              |
| <b>TOTAL ASSETS</b>                                                                    |       | <b>11.7</b>             | <b>2.8</b>              |
| <b>EQUITY AND LIABILITIES</b>                                                          |       |                         |                         |
| <b>Equity</b>                                                                          |       |                         |                         |
| (a) Equity share capital                                                               | 4     | 100.0                   | 100.0                   |
| (b) Other equity                                                                       | 5     | (584.9)                 | (511.1)                 |
| <b>Total equity</b>                                                                    |       | <b>(484.9)</b>          | <b>(411.1)</b>          |
| <b>LIABILITIES</b>                                                                     |       |                         |                         |
| <b>Non current liabilities</b>                                                         |       |                         |                         |
| (a) Financial liabilities                                                              |       |                         |                         |
| (i) Borrowings                                                                         | 6     | -                       | 295.1                   |
| (ii) Other financial liabilities                                                       | 7     | -                       | 55.1                    |
| <b>Total non current liabilities</b>                                                   |       | <b>-</b>                | <b>350.2</b>            |
| <b>Current liabilities</b>                                                             |       |                         |                         |
| (a) Financial liabilities                                                              |       |                         |                         |
| (i) Borrowings                                                                         | 8     | 370.1                   | -                       |
| (ii) Trade payables                                                                    |       |                         |                         |
| Total outstanding dues of micro enterprises and small enterprises                      | 13    | -                       | -                       |
| Total outstanding dues of creditors other than micro enterprises and small enterprises |       | 42.8                    | 61.7                    |
| (iii) Other financial liabilities                                                      | 9     | 77.3                    | -                       |
| (b) Other current liabilities                                                          | 10    | 6.4                     | 2.0                     |
| <b>Total current liabilities</b>                                                       |       | <b>496.6</b>            | <b>63.7</b>             |
| <b>TOTAL LIABILITIES</b>                                                               |       | <b>496.6</b>            | <b>413.9</b>            |
| <b>TOTAL EQUITY AND LIABILITIES</b>                                                    |       | <b>11.7</b>             | <b>2.8</b>              |

The accompanying notes are an integral part of the financial statements

As per our report of even date

**For S R B C & CO LLP**  
Chartered Accountants  
ICAI Firm Registration No. : 324982E/E300003

**For and on behalf of the Board of Directors of  
CARACO PHARMACEUTICALS PRIVATE LIMITED**

**per Parag Gandhi**  
Partner  
Membership no. : 136252  
Pune, May 20, 2026

**Rakeshchandra J. Sinha**  
Director  
DIN: 07340998  
Pune, May 20, 2026

**Prince Kalarickal Elias**  
Director  
DIN: 07292533  
Pune, May 20, 2026

**CARACO PHARMACEUTICALS PRIVATE LIMITED**  
**STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2026**

₹ in Thousand

| Particulars                                                         | Notes | Year ended<br>March 31, 2026 | Year ended<br>March 31, 2025 |
|---------------------------------------------------------------------|-------|------------------------------|------------------------------|
| <b>(I) Expenses</b>                                                 |       |                              |                              |
| Finance costs                                                       | 11    | 24.7                         | 20.4                         |
| Other expenses                                                      | 12    | 49.1                         | 44.2                         |
| <b>(II) Total expenses</b>                                          |       | <b>73.8</b>                  | <b>64.6</b>                  |
| <b>(III) Loss before tax</b>                                        |       | <b>(73.8)</b>                | <b>(64.6)</b>                |
| <b>(IV) Tax expenses</b>                                            | 13    | -                            | -                            |
| <b>(V) Loss for the year (III - IV)</b>                             |       | <b>(73.8)</b>                | <b>(64.6)</b>                |
| <b>(VI) Other comprehensive income</b>                              |       | -                            | -                            |
| <b>(VII) Total comprehensive income for the year</b>                |       | <b>(73.8)</b>                | <b>(64.6)</b>                |
| <b>Earnings per equity share (face value per equity share ₹ 10)</b> | 14    |                              |                              |
| Basic (in ₹)                                                        |       | (7.38)                       | (6.46)                       |
| Diluted (in ₹)                                                      |       | (7.38)                       | (6.46)                       |

The accompanying notes are an integral part of the financial statements

As per our report of even date

**For S R B C & CO LLP**  
Chartered Accountants  
ICAI Firm Registration No. : 324982E/E300003

**For and on behalf of the Board of Directors of  
CARACO PHARMACEUTICALS PRIVATE LIMITED**

**per Parag Gandhi**  
Partner  
Membership no. : 136252  
Pune, May 20, 2026

**Rakeshchandra J. Sinha**  
Director  
DIN: 07340998  
Pune, May 20, 2026

**Prince Kalarickal Elias**  
Director  
DIN: 07292533  
Pune, May 20, 2026

**CARACO PHARMACEUTICALS PRIVATE LIMITED**  
**STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED MARCH 31, 2026**

₹ in Thousand

| Particulars                                    | Equity share capital | Other equity        | Total          |
|------------------------------------------------|----------------------|---------------------|----------------|
|                                                |                      | Reserve and surplus |                |
|                                                |                      | Retained earnings   |                |
| <b>Balance as at March 31, 2024</b>            | <b>100.0</b>         | <b>(446.5)</b>      | <b>(346.5)</b> |
| Loss for the year                              | -                    | (64.6)              | (64.6)         |
| <b>Total comprehensive income for the year</b> | <b>-</b>             | <b>(64.6)</b>       | <b>(64.6)</b>  |
| <b>Balance as at March 31, 2025</b>            | <b>100.0</b>         | <b>(511.1)</b>      | <b>(411.1)</b> |
| Loss for the year                              | -                    | (73.8)              | (73.8)         |
| <b>Total comprehensive income for the year</b> | <b>-</b>             | <b>(73.8)</b>       | <b>(73.8)</b>  |
| <b>Balance as at March 31, 2026</b>            | <b>100.0</b>         | <b>(584.9)</b>      | <b>(484.9)</b> |

The accompanying notes are an integral part of the financial statements

As per our report of even date

**For S R B C & CO LLP**  
Chartered Accountants  
ICAI Firm Registration No. : 324982E/E300003

**For and on behalf of the Board of Directors of**  
**CARACO PHARMACEUTICALS PRIVATE LIMITED**

**per Parag Gandhi**  
Partner  
Membership no. : 136252  
Pune, May 20, 2026

**Rakeshchandra J. Sinha**  
Director  
DIN: 07340998  
Pune, May 20, 2026

**Prince Kalarickal Elias**  
Director  
DIN: 07292533  
Pune, May 20, 2026

**CARACO PHARMACEUTICALS PRIVATE LIMITED**  
**STATEMENT OF CASH FLOW FOR THE YEAR ENDED MARCH 31, 2026**

₹ in Thousand

| Particulars                                                           | Year ended<br>March 31, 2026 |        | Year ended<br>March 31, 2025 |        |
|-----------------------------------------------------------------------|------------------------------|--------|------------------------------|--------|
| <b>A) Cash flow from operating activities</b>                         |                              |        |                              |        |
| Loss before tax                                                       | (73.8)                       |        | (64.6)                       |        |
| Adjustment for:                                                       |                              |        |                              |        |
| Finance cost                                                          | 24.7                         |        | 20.4                         |        |
| <b>Operating loss before working capital changes</b>                  | (49.1)                       |        | (44.2)                       |        |
| <b>Movement in working capital :</b>                                  |                              |        |                              |        |
| Increase / (decrease) in trade payables                               | (18.9)                       |        | 1.0                          |        |
| Increase / (decrease) in current liabilities                          | 4.1                          |        | -                            |        |
| <b>Cash used in operations</b>                                        | (64.1)                       |        | (43.2)                       |        |
| <b>Net cash generated from/(used in) operating activities (A)</b>     |                              | (64.1) |                              | (43.2) |
| <b>B) Cash flow from investing activities (B)</b>                     |                              | -      |                              | -      |
| <b>C) Cash flow from financing activities</b>                         |                              |        |                              |        |
| Proceeds from borrowings                                              |                              |        |                              |        |
| Fellow Subsidiary Company                                             | 75.0                         |        | 40.0                         |        |
| Finance cost                                                          | (2.0)                        |        | (1.6)                        |        |
| <b>Net cash flow from/(used in) financing activities (C)</b>          |                              | 73.0   |                              | 38.4   |
| <b>Net increase / (decrease) in cash and cash equivalents (A+B+C)</b> |                              | 8.9    |                              | (4.8)  |
| Cash and cash equivalents at beginning of the year                    |                              | 2.8    |                              | 7.6    |
| <b>Cash and cash equivalents at the end of the year</b>               |                              | 11.7   |                              | 2.8    |

**Note:**

| <b>Cash and cash equivalents comprises of : (refer note 3)</b> |                         | ₹ in Thousand           |
|----------------------------------------------------------------|-------------------------|-------------------------|
| Particulars                                                    | As at<br>March 31, 2026 | As at<br>March 31, 2025 |
| Balances with banks                                            |                         |                         |
| In current accounts                                            | 11.7                    | 2.8                     |
|                                                                | 11.7                    | 2.8                     |

The accompanying notes are an integral part of the financial statements

As per our report of even date

**For S R B C & CO LLP**

Chartered Accountants

ICAI Firm Registration No. : 324982E/E300003

**For and on behalf of the Board of Directors of**

**CARACO PHARMACEUTICALS PRIVATE LIMITED**

**per Parag Gandhi**

Partner

Membership no. : 136252

Pune, May 20, 2026

**Rakeshchandra J. Sinha**

Director

DIN: 07340998

Pune, May 20, 2026

**Prince Kalarickal Elias**

Director

DIN: 07292533

Pune, May 20, 2026

**CARACO PHARMACEUTICALS PRIVATE LIMITED**  
**NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026**

**1. General Information**

Caraco Pharmaceuticals Private Limited ("the Company") (CIN U24100MH2012FTC225970) is a private limited company incorporated and domiciled in India, having its registered office at FP 145 Ram Mandir Road Vile Parle East Mumbai – 400057, Maharashtra. The Company is a 100% subsidiary of Faststone Mercantile Company Private Limited.

The financial statements were approved for issue in accordance with a resolution of the directors on May 20, 2026.

**2. Material accounting policies**

**2.1 Statement of compliance**

The Company has prepared financial statements for the year ended March 31, 2026 in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015, as amended from time to time, together with the comparative period data as at and for the year ended March 31, 2025 and presentation requirements of Division II of Schedule III to the Companies Act, 2013, (Ind AS compliant Schedule III), as applicable to the standalone financial statements.

**2.2 Basis of preparation and presentation**

The financial statements are presented in ₹ and all values are rounded to the nearest Thousand (₹ 000) upto one decimal, except when otherwise indicated.

The financial statements have been prepared on an historical cost basis, except for certain financial instruments that are measured at fair values at the end of each reporting period, as explained in the accounting policies below.

Historical cost is generally based on the fair value of the consideration given in exchange for goods and services. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, regardless of whether that price is directly observable or estimated using another valuation technique. In estimating the fair value of an asset or a liability, the Company takes into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date. Fair value for measurement and/or disclosure purposes in these financial statements is determined on such a basis, except for share-based payment transactions that are within the scope of Ind AS 102, leasing transactions that are within the scope of Ind AS 116, and measurements that have some similarities to fair value but are not fair value, such as net realisable value in Ind AS 2 or value in use in Ind AS 36.

In addition, for financial reporting purposes, fair value measurements are categorised into Level 1, 2, or 3 based on the degree to which the inputs to the fair value measurements are observable and the significance of the inputs to the fair value measurement in its entirety, which are described as follows:

- Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date;
- Level 2 inputs are inputs, other than quoted prices included within Level 1, that are observable for the asset or liability, either directly or indirectly; and
- Level 3 inputs are unobservable inputs for the asset or liability.

The Company has consistently applied the following accounting policies to all periods presented in these financial statements.

**A. Current vs Non-current**

Based on the time between the acquisition of assets for processing and their realisation in cash and cash equivalents the Company has identified twelve months as its operating cycle for determining current and non-current classification of assets and liabilities in the balance sheet.

**B. Financial instruments**

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

Financial assets and liabilities are recognised when the Company becomes a party to the contractual provisions of the instrument. Financial assets and liabilities are initially measured at fair value. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities (other than financial assets and financial liabilities at fair value through profit or loss) are added to or deducted from the fair value measured on initial recognition of financial asset or financial liability.

Financial assets are subsequently measured at amortised cost if these financial assets are held within a business whose objective is to hold these assets to collect contractual cash flows and the contractual terms of the financial assets give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

Financial liabilities are measured at amortised cost using the effective interest method.

**C. Income tax**

Income tax expense consists of current and deferred tax. Income tax expense is recognised in profit or loss except to the extent that it relates to items recognised in OCI or directly in equity, in which case it is recognised in OCI or directly in equity respectively.

Current tax is the expected tax payable on the taxable profit for the year, using tax rates enacted or substantively enacted by the end of the reporting period, and any adjustment to tax payable in respect of previous years. Current tax assets and tax liabilities are offset where the Company has a legally enforceable right to offset and intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Deferred tax is recognised on temporary differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit.

Deferred tax is measured at the tax rates that are expected to be applied to the temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the end of the reporting period. Deferred tax assets and liabilities are offset if there is a legally enforceable right to set off corresponding current tax assets against current tax liabilities and the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same tax authority on the Company.

A deferred tax asset is recognised to the extent that it is probable that future taxable profits will be available against which the temporary difference can be utilised. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realised.

**D. Provisions, Contingent Liabilities and Contingent Assets**

Provisions are recognised when the Company has a present obligation (legal or constructive) as a result of past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of obligation. The expense relating to a provision is presented in the statement of profit and loss net of any reimbursement.

Contingent liability is disclosed for (i) Possible obligations which will be confirmed only by future events not wholly within the control of the Company or (ii) Present obligations arising from past events where it is not probable that an outflow of resources will be required to settle the obligation or a reliable estimate of the amount of the obligation cannot be made.

Contingent assets are not recognised in the financial statements.

**2.3 Recent Accounting pronouncements:**

The Ministry of Corporate Affairs (MCA) notifies new standards or amendments to the existing standards under Companies (Indian Accounting Standards) Rules as issued from time to time. There is no such notification which would have been applicable from April 01, 2025.

**CARACO PHARMACEUTICALS PRIVATE LIMITED**  
**NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026**

**NOTE : 3**  
**CASH AND CASH EQUIVALENTS**

₹ in Thousand

| Particulars                                                                    | As at<br>March 31, 2026 | As at<br>March 31, 2025 |
|--------------------------------------------------------------------------------|-------------------------|-------------------------|
| Balances with banks                                                            |                         |                         |
| In current accounts                                                            | 11.7                    | 2.8                     |
|                                                                                | <b>11.7</b>             | <b>2.8</b>              |
| There are no conditions or restrictions in using the cash and cash equivalent. |                         |                         |

**NOTE : 4**  
**EQUITY SHARE CAPITAL**

| Particulars                                 | As at<br>March 31, 2026 |               | As at<br>March 31, 2025 |               |
|---------------------------------------------|-------------------------|---------------|-------------------------|---------------|
|                                             | Number of shares        | ₹ in Thousand | Number of shares        | ₹ in Thousand |
| <b>Authorised share capital</b>             |                         |               |                         |               |
| Equity shares of ₹ 10 each                  | 50,000                  | 500.0         | 50,000                  | 500.0         |
|                                             | <b>50,000</b>           | <b>500.0</b>  | <b>50,000</b>           | <b>500.0</b>  |
| <b>Issued, subscribed and fully paid up</b> |                         |               |                         |               |
| Equity shares of ₹ 10 each                  | 10,000                  | 100.0         | 10,000                  | 100.0         |
|                                             | <b>10,000</b>           | <b>100.0</b>  | <b>10,000</b>           | <b>100.0</b>  |

**(a) Reconciliation of the number of equity shares and amount outstanding at the beginning and at the end of reporting period**

| Particulars                                       | As at<br>March 31, 2026 |               | As at<br>March 31, 2025 |               |
|---------------------------------------------------|-------------------------|---------------|-------------------------|---------------|
|                                                   | Number of shares        | ₹ in Thousand | Number of shares        | ₹ in Thousand |
| <b>Reconciliation of fully paid equity shares</b> |                         |               |                         |               |
| Opening balance                                   | 10,000                  | 100.0         | 10,000                  | 100.0         |
| Closing balance                                   | <b>10,000</b>           | <b>100.0</b>  | <b>10,000</b>           | <b>100.0</b>  |

**(b) Details of shareholders holding more than 5% of capital in the Company / Shares held by Holding Company**

| Particulars                           | As at<br>March 31, 2026 |      | As at<br>March 31, 2025 |      |
|---------------------------------------|-------------------------|------|-------------------------|------|
|                                       | Number of shares        | %    | Number of shares        | %    |
| <b>In Equity Shares</b>               |                         |      |                         |      |
| Sun Pharmaceutical Industries Limited | 10,000                  | 100% | 10,000                  | 100% |

**(c) Rights, preference and restrictions attached to equity shares:** The equity shares of the Company, having par value of ₹ 10 per share, rank pari passu in all respects including voting rights and entitlement to dividend.

**(d)** No equity shares have been issued as bonus or shares issued for consideration other than cash or bought back during the period of five years immediately preceding the reporting date.

**NOTE : 5**  
**Other equity**

₹ in Thousand

| Particulars                                                                                                                     | As at<br>March 31, 2026 | As at<br>March 31, 2025 |
|---------------------------------------------------------------------------------------------------------------------------------|-------------------------|-------------------------|
| <b>Reserves and surplus</b>                                                                                                     |                         |                         |
| Retained earnings                                                                                                               |                         |                         |
| Balance as at the beginning of the year                                                                                         | (511.1)                 | (446.5)                 |
| Loss for the year                                                                                                               | (73.8)                  | (64.6)                  |
|                                                                                                                                 | <b>(584.9)</b>          | <b>(511.1)</b>          |
| <b>Nature and purpose of reserve</b>                                                                                            |                         |                         |
| Retained earnings are the profits/(loss) that the Company has earned/incurred till date, less any transfers to general reserve. |                         |                         |
| Refer statement of changes in equity for detailed movement in other equity balance.                                             |                         |                         |

**NOTE : 6**  
**BORROWINGS (NON CURRENT)**

₹ in Thousand

| Particulars                                      | As at<br>March 31, 2026 | As at<br>March 31, 2025 |
|--------------------------------------------------|-------------------------|-------------------------|
| Unsecured, Considered good                       |                         |                         |
| Loan from related parties (refer note 20 and 21) | -                       | 295.1                   |
|                                                  | <b>-</b>                | <b>295.1</b>            |

**NOTE : 7**  
**OTHER FINANCIAL LIABILITIES (NON CURRENT)**

₹ in Thousand

| Particulars                      | As at<br>March 31, 2026 | As at<br>March 31, 2025 |
|----------------------------------|-------------------------|-------------------------|
| Unsecured, Considered good       |                         |                         |
| Interest accrued (refer note 20) | -                       | 55.1                    |
|                                  | <b>-</b>                | <b>55.1</b>             |

**CARACO PHARMACEUTICALS PRIVATE LIMITED**  
**NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026**

**NOTE : 8**

**BORROWINGS (CURRENT)**

₹ in Thousand

| Particulars                                      | As at<br>March 31, 2026 | As at<br>March 31, 2025 |
|--------------------------------------------------|-------------------------|-------------------------|
| Unsecured, Considered good                       |                         |                         |
| Loan from related parties (refer note 20 and 21) | 370.1                   | -                       |
|                                                  | <b>370.1</b>            | <b>-</b>                |

**NOTE : 9**

**OTHER FINANCIAL LIABILITIES (CURRENT)**

₹ in Thousand

| Particulars                      | As at<br>March 31, 2026 | As at<br>March 31, 2025 |
|----------------------------------|-------------------------|-------------------------|
| Unsecured, Considered good       |                         |                         |
| Interest accrued (refer note 21) | 77.3                    | -                       |
|                                  | <b>77.3</b>             | <b>-</b>                |

**NOTE : 10**

**OTHER CURRENT LIABILITIES**

₹ in Thousand

| Particulars           | As at<br>March 31, 2026 | As at<br>March 31, 2025 |
|-----------------------|-------------------------|-------------------------|
| Statutory remittances | 6.4                     | 2.0                     |
|                       | <b>6.4</b>              | <b>2.0</b>              |

**NOTE : 11**

**FINANCE COSTS**

₹ in Thousand

| Particulars                                                          | Year ended<br>March 31, 2026 | Year ended<br>March 31, 2025 |
|----------------------------------------------------------------------|------------------------------|------------------------------|
| Interest expense for financial liabilities carried at amortised cost | 24.7                         | 20.4                         |
|                                                                      | <b>24.7</b>                  | <b>20.4</b>                  |

**NOTE : 12**

**OTHER EXPENSES**

₹ in Thousand

| Particulars                         | Year ended<br>March 31, 2026 | Year ended<br>March 31, 2025 |
|-------------------------------------|------------------------------|------------------------------|
| Rates and taxes                     | 2.5                          | 2.5                          |
| Professional, legal and consultancy | 25.7                         | 21.7                         |
| Payment to auditors                 | 20.9                         | 19.9                         |
| Miscellaneous expenses              | 0.0                          | 0.1                          |
|                                     | <b>49.1</b>                  | <b>44.2</b>                  |

**NOTE : 13**

**TAX RECONCILIATION**

₹ in Thousand

| Particulars                                                                       | Year ended<br>March 31, 2026 | Year ended<br>March 31, 2025 |
|-----------------------------------------------------------------------------------|------------------------------|------------------------------|
| <b>Reconciliation of tax expense</b>                                              |                              |                              |
| Loss before tax                                                                   | (73.8)                       | (64.6)                       |
| Enacted income tax rate (%)                                                       | 25.168%                      | 25.168%                      |
| Income tax calculated at income tax rate                                          | (18.6)                       | (16.3)                       |
| Effect of unused tax losses and tax offsets not recognised as deferred tax assets | 18.6                         | 16.3                         |
| <b>Total tax expense recognised in the Statement of Profit and Loss</b>           | <b>-</b>                     | <b>-</b>                     |

**NOTE : 14**

**EARNINGS PER EQUITY SHARE**

| Particulars                                                                             | Year ended<br>March 31, 2026 | Year ended<br>March 31, 2025 |
|-----------------------------------------------------------------------------------------|------------------------------|------------------------------|
| Loss for the year (₹ in Thousand)- used as numerator for calculating earnings per share | (73.8)                       | (64.6)                       |
| Weighted average number of shares used in computing basic earnings per share            | 10,000                       | 10,000                       |
| Face value per share (in ₹)                                                             | 10                           | 10                           |
| Basic earnings per share (in ₹)                                                         | (7.38)                       | (6.46)                       |
| Diluted earnings per share (in ₹)                                                       | (7.38)                       | (6.46)                       |

**NOTE : 15**

**a) DISCLOSURES UNDER THE MICRO, SMALL AND MEDIUM ENTERPRISES DEVELOPMENT ACT, 2006**

The information regarding Micro and Small Enterprises has been determined to the extent such parties have been identified on the basis of information available with the Company. The company has not received any memorandum ( as required to be filed by the suppliers with notified authority under the Micro, Small and Medium Enterprises Development Act 2006) from vendor claiming the status as micro or small enterprise, hence no disclosures have been made.

**b) Trade payable ageing**

₹ in Thousand

|                                                            | Not due     | Outstanding for following periods from due date of payment |           |           |                   | As at<br>March 31, 2026 |
|------------------------------------------------------------|-------------|------------------------------------------------------------|-----------|-----------|-------------------|-------------------------|
|                                                            |             | Less than 1 year                                           | 1-2 years | 2-3 years | More than 3 years |                         |
| Outstanding dues of other than micro and small enterprises | 42.8        | -                                                          | -         | -         | -                 | 42.8                    |
|                                                            | <b>42.8</b> | <b>-</b>                                                   | <b>-</b>  | <b>-</b>  | <b>-</b>          | <b>42.8</b>             |

₹ in Thousand

|                                                            | Not due | Outstanding for following periods from due date of payment |           |           |                   | As at          |
|------------------------------------------------------------|---------|------------------------------------------------------------|-----------|-----------|-------------------|----------------|
|                                                            |         | Less than 1 year                                           | 1-2 years | 2-3 years | More than 3 years | March 31, 2025 |
| Outstanding dues of other than micro and small enterprises | 61.7    | -                                                          | -         | -         | -                 | 61.7           |
|                                                            | 61.7    | -                                                          | -         | -         | -                 | 61.7           |
|                                                            |         |                                                            |           |           |                   |                |

**NOTE : 16**

**CATEGORIES OF FINANCIAL INSTRUMENTS AND FAIR VALUE HIERARCHY**

₹ in Thousand

| Particulars                    | As at March 31, 2026              |                                               |                |
|--------------------------------|-----------------------------------|-----------------------------------------------|----------------|
|                                | Fair value through profit or loss | Fair value through other comprehensive income | Amortised cost |
| Financial assets               |                                   |                                               |                |
| Cash and cash equivalents      | -                                 | -                                             | 11.7           |
| Financial liabilities          |                                   |                                               |                |
| Borrowing                      | -                                 | -                                             | 370.1          |
| Interest accrued on borrowings | -                                 | -                                             | 77.3           |
| Trade payables                 | -                                 | -                                             | 42.8           |

₹ in Thousand

| Particulars                    | As at March 31, 2025              |                                               |                |
|--------------------------------|-----------------------------------|-----------------------------------------------|----------------|
|                                | Fair value through profit or loss | Fair value through other comprehensive income | Amortised cost |
| Financial assets               |                                   |                                               |                |
| Cash and cash equivalents      | -                                 | -                                             | 2.8            |
| Financial liabilities          |                                   |                                               |                |
| Borrowing                      | -                                 | -                                             | 295.1          |
| Interest accrued on borrowings | -                                 | -                                             | 55.1           |
| Trade payables                 | -                                 | -                                             | 61.7           |

**NOTE : 17**

**FINANCIAL RISK MANAGEMENT**

Commensurate with the size of the Company, its risk management assessment, policies and processes are established to identify and analyse the risks faced by the Company, to set appropriate risk limits and controls, and to monitor such risks and compliance with the same. Risk assessment and management policies and processes are reviewed regularly to reflect changes in market conditions and the Company's activities.

**Market risk**

The Company does not have any market risk such as foreign exchange risk and interest rate risk.

**Liquidity risk**

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company manages its liquidity risk by ensuring, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risk to the Company's reputation.

The table below provides details regarding the contractual maturities of significant undiscounted financial liabilities :

₹ in Thousand

| Particulars                 | Less than 1 year | 1 - 3 years | More than 3 years | As at<br>March 31, 2026 |
|-----------------------------|------------------|-------------|-------------------|-------------------------|
| Borrowing                   | 370.1            | -           | -                 | 370.1                   |
| Trade payables              | 42.8             | -           | -                 | 42.8                    |
| Other financial liabilities | 77.3             | -           | -                 | 77.3                    |
|                             | 490.2            | -           | -                 | 490.2                   |

₹ in Thousand

| Particulars                 | Less than 1 year | 1 - 3 years | More than 3 years | As at<br>March 31, 2025 |
|-----------------------------|------------------|-------------|-------------------|-------------------------|
| Borrowing                   | -                | 295.1       | -                 | 295.1                   |
| Trade payables              | 61.7             | -           | -                 | 61.7                    |
| Other financial liabilities | -                | 55.1        | -                 | 55.1                    |
|                             | 61.7             | 350.2       | -                 | 411.9                   |

**NOTE : 18**

As on March 31, 2026, the Company's accumulated loss of ₹ 584.9 Thousand (March 31, 2025 : ₹ 511.1 Thousand) exceeds the shareholders' funds. As the Company is continuing operational and financial support from its Ultimate Holding Company, these financial statements have been prepared on the 'going concern' assumption.

**CARACO PHARMACEUTICALS PRIVATE LIMITED**  
**NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026**

**NOTE : 19**  
**RATIO**

| Particular                                                                                                                                                                                                                                             | Remarks                                                                    | As at<br>March 31, 2026 | As at<br>March 31, 2025 | Variance (in %) |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------|-------------------------|-------------------------|-----------------|
| <b>(a)</b> Current ratio = (current assets) / (current liabilities)                                                                                                                                                                                    | Change due to Reclassification of borrowings from long term to short term. | 0.02                    | 0.04                    | (50.0%)         |
| <b>(b)</b> Debt equity ratio = (long-term borrowings + short-term borrowings and lease liabilities) / Total equity                                                                                                                                     |                                                                            | (0.76)                  | (0.72)                  | 5.6%            |
| <b>(c)</b> Debt service coverage ratio = {profit/(loss) after tax but before finance costs, depreciation and amortisation and exceptional items} / (finance costs + short-term borrowings + short term Lease liabilities)                              | Change due to Reclassification of borrowings from long term to short term. | (0.12)                  | (2.17)                  | (94.7%)         |
| <b>(d)</b> Return on equity ratio (%) = net profit/(loss) after tax / equity share capital                                                                                                                                                             |                                                                            | (73.80%)                | (64.60%)                | 14.2%           |
| <b>(e)</b> Inventory turnover ratio = (cost of materials consumed + purchase of stock-in-trade + changes in inventories of finished goods, stock-in-trade and work-in-progress) / average inventory                                                    |                                                                            | Not applicable          | Not applicable          | NA              |
| <b>(f)</b> Trade receivables turnover ratio in no. of days = (average trade receivables * no. of days) / revenue from contracts with customers                                                                                                         |                                                                            | Not applicable          | Not applicable          | NA              |
| <b>(g)</b> Trade payable turnover ratio in no. of days = (average trade payable * no. of days) / purchases during the                                                                                                                                  |                                                                            | Not applicable          | Not applicable          | NA              |
| <b>(h)</b> Net capital turnover ratio = revenue from contracts with customers / (current assets - current liabilities)                                                                                                                                 |                                                                            | Not applicable          | Not applicable          | NA              |
| <b>(i)</b> Net profit ratio (%) = net profit/(loss) after tax / total revenue from operations                                                                                                                                                          |                                                                            | Not applicable          | Not applicable          | NA              |
| <b>(j)</b> Return on capital employed (%) = net profit / (loss) after tax / (total assets - total liabilities - intangible assets - intangible assets under development - goodwill + long-term borrowings + short-term borrowings + lease liabilities) |                                                                            | 64.29%                  | 55.69%                  | 15.4%           |
| <b>(k)</b> Return on investment (%) = income generated from FVTPL investment / weighted average FVTPL investment                                                                                                                                       |                                                                            | Not applicable          | Not applicable          | NA              |

**NOTE : 20**  
**DISCLOSURE PURSUANT TO IND AS 24 'RELATED PARTY DISCLOSURES':**

**(A) Name of related parties and description of relationship:**

**(i) Holding Company:**

Sun Pharmaceutical Industries Limited

**(ii) Fellow Subsidiary Company :**

Sun Pharma Laboratories Limited

**(iii) Key management personnel**

**Name**

Mr. Rakeshchandra J. Sinha

Mr. Prince Kalarickal Elias

Mr. Kedar Nath Senapati (Appointed on 29 July 2025)

Mr. Sanjay Jerry (Resigned w.e.f 31 July 2025)

**Designation**

Director

Director

Director

Director

**(B) Summary of the transaction with related parties as per Ind AS 24**

₹ in Thousand

| Particulars                                                           | Year ended<br>March 31, 2026 | Year ended<br>March 31, 2025 |
|-----------------------------------------------------------------------|------------------------------|------------------------------|
| <b>Loan taken from :</b><br>Sun Pharma Laboratories Limited           | 75.0                         | 40.0                         |
| <b>Interest on loan taken from</b><br>Sun Pharma Laboratories Limited | 24.7                         | 20.4                         |

**(C) Outstanding balance with related parties as per Ind AS 24**

₹ in Thousand

| Particulars                                                             | As at<br>March 31, 2026 | As at<br>March 31, 2025 |
|-------------------------------------------------------------------------|-------------------------|-------------------------|
| <b>Loan taken from :</b><br>Sun Pharma Laboratories Limited             | 370.1                   | 295.1                   |
| <b>Interest Accrued on borrowing</b><br>Sun Pharma Laboratories Limited | 77.3                    | 55.1                    |

**(D) Terms and conditions of transactions with related parties**

The transactions with related parties are made on an arm's length basis. Outstanding trade balances at the year end are unsecured and settlement occurs in cash. There have been no guarantees provided or received for any related party receivables or payables.

As per Holding Company RPT disclosure policy, there are no material related party transactions during the year ended March 31, 2026.

**CARACO PHARMACEUTICALS PRIVATE LIMITED**  
**NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026**

**NOTE : 21**

Unsecured loan from related party ₹ 370.1 Thousand (March 31, 2025: ₹ 295.1 Thousand). The loan is repayable by March 25, 2027. The loan has been availed at 7.50%.

**NOTE : 22**

**OTHER MATTERS**

- a) No proceeding have been initiated or pending against the Company under the Benami Transactions (Prohibitions) Act, 1988 (45 of 1988) and the Rules made thereunder.
- b) The company does not have any transactions with companies struck off under section 248 of the Companies Act, 2013 or section 560 of the Companies Act, 1956.
- c) The provisions of Section 135 of the Companies Act, 2013 are not applicable to the Company, as the Company has not met the prescribed thresholds of net worth, turnover, or net profit during the relevant financial year(s).
- d) The Company has not traded or invested in crypto currency or virtual currency during the financial year.
- e) The Company has not granted any loans or advances in the nature of loans to promoters, directors, KMPs either severally or jointly with any other person.
- f) No funds have been advanced or loaned or invested either from borrowed funds or share premium or any other sources or kind of funds by the Company to or in any other person or entity, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of
- g) No funds have been received by the Company from any person or entity, including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
- h) The Company does not have any transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961.
- i) The Company has not been sanctioned working capital limits from banks or financial institutions during any point of time of the year on the basis of security of current assets.
- j) The Company has not been declared wilful defaulter by any bank or financial institution or government or any government authority.

**NOTE : 23**

The Company has used accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software. Further, there are no instance of audit trail feature being tampered with. Additionally, the audit trail of relevant prior years has been preserved by the Company in accordance with statutory record retention requirements to the extent it was enabled and recorded in those respective years, except that for two applications where the audit trail relating to direct changes made using privileged/administrative access rights has not been preserved for the period May 24 to November 24.

**NOTE : 24**

Previous year's figure has been regrouped and reclassified, wherever necessary.

---

As per our report of even date

**For S R B C & CO LLP**  
Chartered Accountants  
ICAI Firm Registration No. : 324982E/E300003

**per Parag Gandhi**  
Partner  
Membership no. : 136252  
Pune, May 20, 2026

**For and on behalf of the Board of Directors of**  
**CARACO PHARMACEUTICALS PRIVATE LIMITED**

**Rakeshchandra J. Sinha**  
Director  
DIN: 07340998  
Pune, May 20, 2026

**Prince Kalarickal Elias**  
Director  
DIN: 07292533  
Pune, May 20, 2026